OACC

10.7100.19%
AS

Alvin Shih

Independent Director

Dr. Alvin Shih, M.D. M.B.A. was Executive Chair at Imbria Pharmaceuticals, Inc until September 2025. and serves as its CEO since April 2025 and serves as its Director. He is Independent Director of Oaktree Acquisition Corp. III Life Sciences since October 23, 2024. He is an Independent Director at Zevra Therapeutics, Inc. since January 20, 2024. He serves as Director of TENZA, INC since November 2021. He as Chief Executive Officer & President at Catamaran Bio, Inc. since February 2021 and has been its Director since February 2021. He served as Chief Executive Officer and President at Disarm Therapeutics, Inc. since July, 2019 to December 2020 and serves as its Director since October 2020. He served as Atlas Advisor at Atlas Venture L.P. till 2021. Before joining Disarm, he served as Chief Executive Officer of Enzyvant Therapeutics. from November 2016 to February 2019. Dr. Shih served as Head of Research & Development and Executive Vice President at Retrophin, Inc. from May 2014 to October 31, 2016. Dr. Shih has broad experience in drug development, spanning multiple indications with a focus on rare diseases, including as the chief operating officer and founding member of Pfizer Inc.’s (NYSE: PFE) rare disease research unit from May 2010 to May 2014. At Pfizer, he was responsible for strategic initiatives and operational functions of the Rare Disease Research Unit. Prior to Pfizer, Dr. Shih was a senior engagement Manager for L.E.K. Consulting, LLC, where he provided life sciences companies with strategic counsel on M&A transactions and growth development. He was also a management consultant for L.E.K. Consulting and McKinsey & Company. Since July 2024, Dr. Shih has served on the board of directors of Imbria Pharmaceuticals. Dr. Shih began his career as a management consultant at LEK Consulting. Dr. Shih earned a B.A. in biology from Vanderbilt University, an MBA in health industry management from Northwestern University Kellogg School of Management and an MD from the University of Alabama School of Medicine. He is Board certified by the American Board of Internal Medicine. In his career, Dr. Shih completed his residency training in internal medicine at Massachusetts General Hospital.

Positions